Last reviewed · How we verify

Komzifti — Competitive Intelligence Brief

Komzifti (ZIFTOMENIB) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Menin Inhibitor [EPC]. Area: Oncology.

marketed Menin Inhibitor [EPC] Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Komzifti (ZIFTOMENIB) — Kura. Komzifti works by inhibiting the menin protein, which is involved in the regulation of gene expression in cancer cells.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Komzifti TARGET ZIFTOMENIB Kura marketed Menin Inhibitor [EPC] 2025-01-01
MK-8527 MK-8527 Merck Sharp & Dohme LLC phase 3 Menin inhibitor Menin (MEN1 protein)
BGB-15025 BGB-15025 BeiGene phase 3 Menin inhibitor Menin (MEN1 protein)
BMS-986365 BMS-986365 Celgene phase 3 Menin inhibitor Menin (MEN1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Menin Inhibitor [EPC] class)

  1. Kura · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Komzifti — Competitive Intelligence Brief. https://druglandscape.com/ci/ziftomenib. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: